Inhibrx Inc

Inhibrx — Investor Presentation (January 2021)

31 slides from Inhibrx's investor presentation, Jan 5, 2021

  1. Slide 1: Outcomes Focused Innovation Driven January 2021

    Outcomes Focused Innovation Driven January 2021

  2. Slide 2: Presentation disclaimer

    2 This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminol

  3. Slide 3: Key investment highlights

    3 Key investment highlights Proprietary single domain antibody (sdAb) platform Potential rapid path to first approval and financial sustainability Experienced leadership team aligned with investors Validation from industry leading partnersFour clinical programs with upcoming readouts

  4. Slide 4: Four differentiated clinical programs addressing large market opportunities

    4 Four differentiated clinical programs addressing large market opportunities INBRX-109 Tetravalent DR5 agonist + Single agent activity in difficult to treat tumors + Potential rapid path to approval in chondrosarcoma, registration study starting in mid 2021 + First combination cohorts initiated INB

  5. Slide 5: Inhibrx's modular sdAb platform

    5 Inhibrx’s modular sdAb platform 75 kDa 90 kDa 105 kDa 120 kDa 135 kDa 75 kDa 90 kDa 105 kDa 120 kDa 135 kDa Inhibrx multivalent formats Inhibrx multispecific formats Precision engineering Readily manufactured at high yields using standard processes Versatile and innovative formats enable validated

  6. Slide 6: INBRX-109 Tetravalent DR5 Agonist

    INBRX-109 Tetravalent DR5 Agonist

  7. Slide 7: Death receptor target overview

    7 Death receptor 5 target overview Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) DR5 activation naturally eliminates damaged and neoplastic cells Higher order clustering of DR5 is required to drive signaling Potential to treat cancers th

  8. Slide 8: Valency drives DR5-mediated apoptosis

    8 Valency drives DR5-mediated apoptosis INBRX-109 is 100x more potent in preclinical assays compared to first generation bivalent and trivalent agonists Impact of valency on DR5 induced tumor cell death 1 10 25 50 75 100 % V ia bi lit y 0 Concentration (nM) 10-110-210-310-410-5 TRAIL (Trivalent) INB

  9. Slide 9: INBRX-109 engineered to avoid hepatotoxicity

    9 INBRX-109 engineered to avoid hepatotoxicity Tetrameric INBRx-109 did not induce hepatic cell apoptosis; lacks sites for PE-ADAs mediated crosslinking Human hepatocyte toxicity assay Hepatocytes may be subject to on-target toxicity for DR5 pathway agonism Previous tetravalent DR5 agonist failed in

  10. Slide 10: Ph1 INBRX-109 trial design and status

    10 Ph1 INBRX-109 trial design and status Chondrosarcoma Synovial sarcoma Colorectal adenocarcinoma 20 PART 2: Dose expansion cohorts Initial expansion cohort indications were selected based on in vitro and in vivo sensitivities to the DR5 pathway and clinical data from prior DR5 agonists PART 3: Com

  11. Slide 11: Chondrosarcoma fast to market opportunity

    11 Therapeutic IPI-926 (HH) Control arm Placebo Subject number 100 (2:1) Efficacy data PFS 3.7 mo vs 2.9 mo Placebo Comment Negative study Fast to market opportunity ~1,400 cases per year Incidence rate of ~1 in 200,000 persons per year USA Worldwide Chondrosarcoma PFS from failed study *The figures

  12. Slide 12: INBRX-109 data and registration-enabling study design in chondrosarcoma

    12 INBRX-109 data and registration-enabling study design in chondrosarcoma INBRX-109 in chondrosarcoma: Cut point 17-Oct-2020, study ongoing Disclaimer: Per investigator assessments, not confirmed by central radiology review, and data subject to change ► Ongoing PR=Partial Response, SD=Stable Diseas

  13. Slide 13: INBRX-109 potential in multiple indications

    13 INBRX-109 potential in multiple indications INITIAL INDICATIONS STUDIES INITIATED IN Q3 OF 2020 FUTURE POTENTIAL OPPORTUNITIES Mesothelioma Chemotherapy combination or single agent Pancreatic – 2nd line FOLFIRI Mesothelioma Cis-/Carboplatin & Pemetrexed Synovial sarcoma Solid tumors + IAP antagon

  14. Slide 14: INBRX-106 Hexavalent OX40 Agonist

    INBRX-106 Hexavalent OX40 Agonist

  15. Slide 15: INBRX-106 hexavalent OX40 agonist

    15 INBRX-106 hexavalent OX40 agonist OX40 is a co-stimulatory receptor on activated T-cells Hexavalent engagement of OX40: • Provides co-stimulation to activated T-cells • Reverses regulatory T-cell induced immune suppression • Enhances T-cell functionality; additional benefit in combination with PD

  16. Slide 16: INBRX-106 is a best-in-class OX40 agonist

    16 INBRX-106 is a best-in-class OX40 agonist INBRX-106 incorporates all known attributes for optimal OX40 agonism - Increased valency and effector enabled Fc domain have both been empirically shown to promote activity - Lack of ligand blocking activity may provide APC activation and natural cellular

  17. Slide 17: Hexavalent OX40 agonism potently induces anti-tumor immune activation

    17 Hexavalent OX40 agonism potently induces anti-tumor immune activation Hexavalent OX40 agonism impacts multiple cell populations to tip the balance toward tumor eradication Redmond lab Earle A. Chiles Research Institute Providence Cancer Institute

  18. Slide 18: INBRX-106 trial design and status

    18 Phase 1 INBRX-106 trial design and status Initial data from Part 1 PARTS 2 & 4: Expansion cohorts INBRX-106 (Multiple dosing schedules) PARTS 1 & 3: Dose escalation finished Dec 2020 - Dose escalation in combination with Keytruda™ initiated - Signs of single agent activity, including prior PD-1 f

  19. Slide 19: INBRX-105 PD-L1 x 4-1BB Multispecific

    INBRX-105 PD-L1 x 4-1BB Multispecific

  20. Slide 20: INBRX-105 tumor-targeted 4-1BB agonist

    20 INBRX-105 tumor-targeted 4-1BB agonist 41BB agonism boosts anti-tumor T-cell activity INBRX-105, a PD-L1 dependent 4-1BB agonist: • Provides potent PD-1/PD-L1 blockade • 4-1BB agonism only at sites of PD-L1 expression, provides local co-stimulation to TILs • Engineered to avoid hepatoxicity liabi

  21. Slide 21: INBRX-105 reversed suppression by PD-L1

    21 INBRX-105 reversed suppression by PD-L1 *synthesized from sequences disclosed in WO 2018/056821 MCLA-145 analog* displayed ~20 fold reduction in potency Data indicated potential advantage of bivalent PD-L1 binding and blockade INBRX-105 potently reversed PD-L1/PD-1 suppression with activity equiv

  22. Slide 22: INBRX-105 trial design and status

    22 Phase 1 INBRX-105 trial design and status First in human Phase 1 trial started Feb. 2019 PART 1: Dose escalation INBRX-105 ongoing Locally advanced or metastatic solid tumors PDL1+ NSCLC PDL1+ Melanoma PDL1+ Basket PART 4: Dose expansion INBRX-105 + Keytruda™ planned N=20 N=20 N=20 80 patient com

  23. Slide 23: INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

    INBRX-101 Recombinant Alpha-1 Antitrypsin Fc-fusion Protein

  24. Slide 24: AATD and current therapy shortcomings

    24 AATD and current therapy shortcomings AAT Serum levels in patients receiving weekly pdAAT Opportunity: The global AATD augmentation therapy market size was valued at $1.1B annually in 2018 and projected to reach $1.9B by the end of 2026 What is AATD? AATD is an orphan respiratory inherited diseas

  25. Slide 25: INBRX-101 optimizing AAT augmentation therapy

    25 INBRX-101 optimizing AAT augmentation therapy AAT Half life extension mutations Elimination of oxidation-prone residues Fc INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein • Potential to extend the dosing range, from weekly to every three weeks, while maintaining patien

  26. Slide 26: INBRX-101: first human pharmacokinetic data

    26 INBRX-101: first human pharmacokinetic data PK profile of first 5 patients: 10 mg/kg INBRX-101 Predicted mean serum AAT levels: 120 mg/kg of INBRX-101 every 3 weeks Preliminary human PK data for first five subjects dosed with 10 mg/kg single IV dose of INBRX-101 • Consistent with preclinical esti

  27. Slide 27: Near term expected clinical milestones

    27 H2 2020 H1 2021 H2 2021 Near term expected clinical milestones INBRX-109 (DR5) registration-enabling trial initiation- chondrosarcoma INBRX-101 (AAT) Phase 1 data INBRX-105 (PDL-1x41BB) dose escalation data INBRX-105 (PDL-1x41BB) expansion cohort data INBRX-109 (DR5) Chondrosarcoma updated data a

  28. Slide 28: 11025 N. Torrey Pines Rd, Ste La Jolla, CA 92037 www.inhibrx.com

    11025 N. Torrey Pines Rd, Ste 140 La Jolla, CA 92037 www.inhibrx.com

  29. Slide 29: Supplementary Slides

    Supplementary Slides

  30. Slide 30: INBRX-109 data in malignant pleural mesothelioma

    30 INBRX-109 data in malignant pleural mesothelioma Cut point 17-Oct-2020, study ongoing Disclaimer: Per investigator assessments, not confirmed by central radiology review, and data subject to change PR=Partial Response, SD=Stable Disease, PD=Progressive Disease, NE=Not Evaluable ► Ongoing *Off-stu

  31. Slide 31: INBRX-109 - favorable Adverse Event (AE) profile

    31 INBRX-109 - favorable Adverse Event (AE) profile AE Term AE related to INBRX-109 (very likely, probable, possible) Grade per CTCAEv5.0 Gr1&2 (N) Gr1&2 (%) Gr=/>3 (N) Gr=/>3 (%) All Grade (N) All Grade (%) Fatigue 14 18 0 0 14 18 AST increased 7 9 3 4 10 13 ALT increased 7 9 3 4 10 13 Nausea 6 8 1

Inhibrx — Investor Presentation (January 2021) on 6ix